Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 30 November 2021, 09:13 HKT/SGT
Share:
    

Source: Eisai
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
Developing solutions such as smartphones equipped with the brain health check tool "NouKNOW"

TOKYO, Nov 30, 2021 - (JCN Newswire) - Eisai Co., Ltd. and FCNT LIMITED announced today that both companies have entered into a business alliance agreement aiming to support people living with dementia and to prevent dementia, through developing solutions for maintaining brain performance. Both companies will construct an ecosystem with the aim of supporting people living with and preventing dementia ("Dementia Ecosystem"), with integrating Eisai's wealth of experience and knowledge including drug creation and disease awareness activities as well as Eisai's solution measures such as digital technology, in the area of dementia, and FCNT's products such as smartphones designed to offer outstanding usability for the elderly as well as FCNT's services including "Raku Raku Community" on SNS targeting such smartphone users. With constructing a "Dementia Ecosystem", both companies aim to contribute to the solution of dementia, which is one of the important social issues in an aging society.

The initiatives planned under the alliance are as follows.

1. The "NouKNOW" will be installed on the "Raku Raku Smartphone"
The "Raku Raku Smartphone F-52B" developed and manufactured by FCNT will be equipped with the digital tool for self-assessment of brain performance (brain health) "NouKNOW" (pronounced "NOH-NOH", non-medical equipment) distributed by Eisai. It is scheduled to be released by NTT DOCOMO, INC. in or after February 2022. This will be the first time that "NouKNOW" is deployed as a function that can be operated on a smartphone. F-52B users will be provided with brain performance checks at no cost by "NouKNOW" up to 4 times a year.

2. Developing solutions for retaining good health and the disease prevention
Eisai and FCNT will develop highly convenient solutions for the prevention of dementia, such as identifying future health concerns and predicting risks, with utilizing FCNT's healthcare information infrastructure to accumulate data available among users, including step count, step speed and heart rate, as well as its management capacity to develop membership services such as "Raku-Raku Community" (2.4 million members as of August 2021. Based on available information by FCNT), an SNS service for seniors with a membership system, in addition to Eisai's know-how based on various data in the area of dementia. Furthermore, the both companies aim to deploy the new solutions developed based on this alliance for corporate customer, including businesses and regional governments, as a packaged solution that combines products and services owned by not only Eisai and FCNT but also other industries and organizations.

Eisai and FCNT will address and resolve the social issue related to dementia, and promote co-creation of value toward realizing a healthy and long-lived society through contributing to the construction of a "Dementia Ecosystem" by combining the strengths of the both companies.

For more information, visit https://www.eisai.com/news/2021/news202195.html.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: